T cells

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Ad26 Ad26.COV2.S Ad26.COV2.S vaccine Adenovirus administration adverse event age All participants Antibody Response assigned authority candidate vaccine CD4+ T-cell CD8+ T-cell Cohort cohorts collected coronavirus coronavirus disease Coronavirus disease 2019 COV1001 COV2.S Department development dose Factor fatigue Fever full-length geometric mean geometric mean titer GMT headache healthy High dose Human increase in Infection Injection-site pain Interim Johnson & Johnson less low dose milliliter multicenter myalgia Neutralizing-antibody Neutralizing-antibody titers Older pandemic participant phase Placebo placebo-controlled primary end point profile provided Randomly reached reactogenicity receive regimen remained reported research and development respiratory response responses Result robust SARS-CoV-2 SARS-CoV-2 spike protein second dose serotype severe acute respiratory syndrome Coronavirus Spike protein Support systemic systemic adverse events T cells T-cell responses titer titers Trial two-dose regimen type 1 helper Vaccine vaccine candidate vaccine dose Viral viral particle wild-type virus
[DOI] 10.1056/NEJMoa2034201 PMC 바로가기 [Article Type] Clinical Trial